Enlivex Therapeutics Ltd
NASDAQ:ENLV
Enlivex Therapeutics Ltd
Research & Development
Enlivex Therapeutics Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Research & Development
-$9.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$12.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$67.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$5.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Research & Development
-$15.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Research & Development
-₪10.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Enlivex Therapeutics Ltd
Glance View
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
See Also
What is Enlivex Therapeutics Ltd's Research & Development?
Research & Development
-9.6m
USD
Based on the financial report for Sep 30, 2025, Enlivex Therapeutics Ltd's Research & Development amounts to -9.6m USD.
What is Enlivex Therapeutics Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-2%
Over the last year, the Research & Development growth was 18%. The average annual Research & Development growth rates for Enlivex Therapeutics Ltd have been 19% over the past three years , -11% over the past five years , and -2% over the past ten years .
